eShowcase: ClearTrial 2.0
Web-based dashboard places clinical trial designers squarely in the driver's seat
Web-based dashboard places clinical trial designers squarely in the driver's seat
ClearTrial, LLC (Oakbrook Terrace, IL) has released version 2.0 of its clinical trial operations planning software to help biopharm companies and CROs plan, budget, and optimize the operational design of clinical trials.
The heart of this latest version is a Web-based "dashboard" that offers a view of monthly budgets, accruals forecasts, study metrics, cycle-time dates, costs, and FTE/resource requirements. Also new is support for multiple outsourcing strategies, full-service outsourcing, hybrid studies, staff augmentation, and internal studies.
Other adornments to this version include the ability to compare cost and timelines between internal studies and outsourced ones, as well as assign study tasks to multiple service providers by function or country. Collaborative planning is also now possible between departments, business units, and strategic partners.
ClearTrial 2.0 is a J2EE-compliant, native Web-based application running over an Oracle database.
ClearTrial, LLC, (630) 424-1601, www.cleartrial.com
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
